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In Brief
Extramedullary hematopoiesis (EMH) is
the formation of blood cells outside the
bone marrow, usually in response to
pathological conditions. Gawish et al.
report here that STAT1 signaling in
myeloid cells restricts early murine
cytomegalovirus (MCMV) replication and
promotes splenic EMH during acute
infection and sterile inflammation.
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Cytomegalovirus (CMV) has a high prevalence
worldwide, is often fatal for immunocompromised
patients, and causes bone marrow suppression.
Deficiency of signal transducer and activator of
transcription 1 (STAT1) results in severely impaired
antiviral immunity. We have used cell-type restricted
deletion of Stat1 to determine the importance of
myeloid cell activity for the defense against murine
CMV (MCMV). We show that myeloid STAT1 limits
MCMV burden and infection-associated pathology
in the spleen but does not affect ultimate clearance
of infection. Unexpectedly, we found an essential
role of myeloid STAT1 in the induction of extramedul-
lary hematopoiesis (EMH). The EMH-promoting func-
tion of STAT1 was not restricted to MCMV infection
but was also observed during CpG oligodeoxynu-
cleotide-induced sterile inflammation. Collectively,
we provide genetic evidence that signaling through
STAT1 in myeloid cells is required to restrict MCMV
at early time points post-infection and to induce
compensatory hematopoiesis in the spleen.
INTRODUCTION
Cytomegalovirus (CMV), a member of the herpesvirus family,
causes acute infection and establishes latency after resolution2394 Cell Reports 26, 2394–2406, February 26, 2019 ª 2019 The Aut
This is an open access article under the CC BY-NC-ND license (http://of the primary disease. Sero-positivity in the human population
is up to 90%, with the potential of CMV to reactivate (Staras
et al., 2006). Although the infection is usually asymptomatic
in immunocompetent hosts, it can be fatal for immuno-
compromised patients, who develop severe immunopathology,
including pneumonia, bone marrow failure (Almeida-Porada
and Ascensao, 1996; Griffiths et al., 2015; Sing and Ruscetti,
1995), splenomegaly, and splenic rupture (Alliot et al., 2001;
Duarte et al., 2003). Despite the availability of antiviral drugs (Ein-
sele et al., 2014), CMV is still a threat for the elderly (Pawelec
et al., 2012), newborns, transplantation patients (Navarro,
2016), and intensive care unit patients (Frantzeskaki et al.,
2015) and represents the most frequent cause of death among
AIDS patients (Griffiths et al., 2015). Experimental infection of
mice with murine CMV (MCMV) is established as a robust
research model for human CMV (HCMV) infection (Brune et al.,
2001). Similar to HCMV, MCMV has broad cellular and tissue
tropism and can infect a wide range of immune and non-immune
cells, such as epithelial cells, endothelial cells (Landolfo et al.,
2003; Reddehase et al., 1985. 2002), monocytes, and macro-
phages (Henry et al., 2000; Hsu et al., 2009; Stoddart et al.,
1994). In general, a fast and profound innate immune response
is necessary to control CMV infection. It includes activation of
dendritic cells (DCs) and natural killer (NK) cells and directs
adaptive immune responses, which are crucial to clear the pri-
mary infection and to prevent reactivation of persistent CMV (Fo-
dil-Cornu and Vidal, 2008; Loewendorf and Benedict, 2010).
Although the protective functions of NK cells and DCs during
CMV infection are well described (Alexandre et al., 2014; Brink-
mann et al., 2015; Lisnic et al., 2015), only a few studieshor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
addressed the role of macrophages and monocytes. In the liver,
resident macrophages and newly recruitedmonocytesmodulate
hepatitis (Borst et al., 2017) and facilitate recruitment and activa-
tion of NK cells and viral clearance (Hokeness et al., 2005; Sala-
zar-Mather et al., 2002). Macrophage depletion with clodronate-
loaded liposomes increasesMCMVburden (Hanson et al., 1999),
further supporting a protective role of these cells during infec-
tion. In contrast, monocytes and macrophages are target cells
for MCMV (Hanson et al., 1999) and serve as dissemination
vehicles to promote virus spread (Daley-Bauer et al., 2014).
Although it is still a matter of debate, they may also be a latent
reservoir for CMV (Koffron et al., 1998; Marquardt et al., 2011).
Signal transducer and activator of transcription 1 (STAT1) is a
crucial component of the antiviral defense. The most prominent
function of STAT1 is to mediate responses to all types of inter-
ferons (IFNs) (Boisson-Dupuis et al., 2012; Najjar and Fagard,
2010). Upon tyrosine phosphorylation by receptor-associated
Janus kinases (JAKs), activated STAT1 translocates to the
nucleus and induces several hundred genes whose products
regulate a variety of cellular functions, such as antiviral activity,
proliferation, and apoptosis. STAT1 not only induces cell-
intrinsic antiviral activity but also has immune modulatory prop-
erties in cells of the innate and adaptive immune system (Najjar
and Fagard, 2010). Mice deficient for STAT1 (Stat1/) are highly
susceptible to bacterial (Decker et al., 2002; Meraz et al., 1996)
and viral infections, including MCMV (Durbin et al., 1996; Gil
et al., 2001). Consistently, patients carrying loss-of-function
mutations in the STAT1 gene are severely immunocompromised
and suffer from life-threatening bacterial and viral infections
(Boisson-Dupuis et al., 2012).
Macrophages are widely used to study antiviral mechanisms,
including those effective against CMV, and viral evasion strate-
gies. Pre-treatment with IFNs makes them less susceptible for
infections (Kropp et al., 2011; Presti et al., 2001), and the
absence of IFN signaling components results in a failure to com-
batMCMV infection in vitro (Kropp et al., 2011; Presti et al., 2001;
Strobl et al., 2005). However, it has remained elusive whether
the antiviral activity of macrophages contributes to the immune
defense against MCMV in vivo. We made use of mice that
lack STAT1 in monocytes, macrophages (M), and polymorpho-
nuclear neutrophils (PMNs; granulocytes), that is, Stat1flox/flox/
LysMCremice (herein referred to as Stat1DM/PMN mice), to study
the role of STAT1-mediated functions of myeloid cells in the
immune defense against MCMV.
Our study revealed that STAT1 in myeloid cells (i.e., mono-
cytes, macrophages, and/or neutrophils) is crucial for the early
control of MCMV infection and for induction of splenic extrame-
dullary hematopoiesis (EMH) during viral infection and sterile
inflammation. Intriguingly, the EMH phenotype is independent
of the individual presence of the receptors for type I and II IFNs
or IL-27.
RESULTS
Myeloid Cells Suppress Early MCMV Replication in the
Spleen via STAT1
To investigate the importance of STAT1 signaling inmyeloid cells
in the anti-MCMV defense, we infected Stat1DM/PMN and Stat1fl/flmice with salivary gland-derived MCMV (SG-MCMV) and
determined viral titers in spleen and liver at 3 and 7 days post-
infection (p.i.). In immunocompetent mice, MCMV replication is
very efficiently controlled in the spleen (Sacher et al., 2012; Tay
and Welsh, 1997), and viral load was close to the detection limit
in Stat1fl/fl mice (Figure 1A). Viral titers were increased in
Stat1DM/PMN mice compared with littermate controls and,
as expected, even higher in mice that completely lack STAT1
(Stat1/) (Figure 1A, left). Viral load remained elevated in
Stat1DM/PMN mice on day 7 p.i., although it considerably
decreased compared with day 3 p.i. (Figure 1A, right). Thus, in
contrast to Stat1/ mice, which succumb to MCMV infection
around day 5 p.i., Stat1DM/PMN mice are capable of controlling
the infection. Viral load in the liver did not significantly differ be-
tween Stat1DM/PMN and Stat1fl/fl mice, although in Stat1DM/PMN
animals, it appeared to be intermediate between Stat1fl/fl and
Stat1/ mice at day 3 p.i. (Figure 1B). MCMV was cleared
from livers of Stat1fl/fl and Stat1DM/PMN mice at day 7 p.i. (data
not shown). Consistently, MCMV genome copies in spleens,
but not livers, were increased in Stat1DM/PMN compared with
Stat1fl/fl mice at day 3 p.i. (Figures S1A and S1B). Mice that
express only the Cre recombinase (LysM-Cre, Stat1+/+ Cre) did
not differ from Stat1fl/fl mice with respect to the amount of viral
genomes in spleen and liver (Figures S1A and S1B).
Immunohistological analysis for the immediate-early viral
protein 1 (IE1, m123) revealed a profound increase inm123+ cells
in spleens from Stat1DM/PMN compared with Stat1fl/fl mice (Fig-
ure 1C, top). Infected cells were localized in the red pulp and
the marginal zone in Stat1DM/PMN mice, whereas the splenic
architecture was completely lost in Stat1/ mice, and m123+
cells were detectable throughout the whole organ (Figure 1C,
top). In livers, the number of m123+ cells was similar in
Stat1DM/PMN and Stat1fl/fl mice, whereas it was strongly
increased in Stat1/ mice (Figure 1C, bottom).
AlthoughMCMVgets cleared from spleen and liver around day
7 p.i., viral titers start to increase in the salivary gland, the site
where the virus persists and may get reactivated (Krmpotic
et al., 2003). MCMV titers in the salivary glands of Stat1DM/PMN
mice were higher than in those of control mice on day 14 p.i. (Fig-
ure 1D, left). The difference was less pronounced on day 21 p.i.
(Figure 1D, middle) and infectious virus was cleared at 3 months
p.i. in mice of both genotypes (Figure 1D, right). Furthermore, the
abundance of MCMV genomes was similar in Stat1DM/PMN and
Stat1fl/fl mice at 3 months p.i. (Figure S1C). Thus, STAT1 in
myeloid cells contributes to the early control of MCMV in spleen
and salivary glands but is dispensable for the ultimate control of
the infection.
Myeloid STAT1 Protects from MCMV-Induced Spleen
Pathology
To test whether the increased MCMV load in Stat1DM/PMN mice
affects tissue damage, we performed histopathological analyses
of H&E-stained spleen and liver sections at 3, 5, and 14 days p.i.
(Figures 2A and 2B). Spleen pathology showed mainly cell death
and marginal zone cell proliferation, peaked at 3 days p.i., and
was higher in Stat1DM/PMN than in Stat1fl/flmice (Figure 2A). Liver
pathology was most pronounced at day 5 p.i. and remained un-
affected by the absence of STAT1 in myeloid cells (Figure 2B).Cell Reports 26, 2394–2406, February 26, 2019 2395
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Figure 1. Stat1DM/PMNMice Have Increased
MCMV Load in Spleen and Salivary Glands
Compared with Stat1fl/fl Mice but Are
Capable of Clearing the Infection
(A and B) Viral titers in (A) spleen and (B) liver
at times indicated in Stat1fl/fl, Stat1DM/PMN, and
Stat1/ mice after intraperitoneal (i.p.) infection
with 53 104 plaque-forming units (PFUs) ofMCMV
(n = 11–14, N = 2 or 3).
(C) Spleen and liver sections stained for theMCMV
m123 protein at day 3 p.i. (left scale bar, 100 mm;
right scale bar, 20 mm).
(D) Viral titers in salivary gland of MCMV-infected
Stat1fl/fl and Stat1DM/PMN mice at times indicated
(n = 15–20, N = 2).
DL, detection limit; horizontal lines and error bars
indicate mean ± SEM; n, biological replicates;
N, experimental repetitions. *p% 0.05, **p% 0.01,
and ****p% 0.0001.
See also Figure S1.Consistent with this finding, plasma levels of aspartate amino
transaminase (AST) and alanine amino transaminase (ALT), two
well-established markers for liver injury, were similar in both ge-
notypes on days 3 and 5 p.i. (Figure S2A). Previous studies have
shown that type I IFN-dependent production of CCL2 by liver-
resident macrophages is required for the recruitment of inflam-
matory monocytes, which subsequently recruit antiviral NK cells
through the secretion of CCL5 (Crane et al., 2009; Hokeness
et al., 2005). We did not observe differences in the local expres-
sion ofCcl2 andCcl5mRNAs (Figure S2B), the recruitment of NK
cells to the liver and the frequency of IFNg+ liver NK cells (Figures
S2C and S2D) between Stat1DM/PMN and Stat1fl/fl mice.
To confirm increased splenocyte death in Stat1DM/PMN mice,
we performed immunohistochemical staining for cleaved cas-
pase-3 (Casp3). The number of apoptotic splenocytes pro-
foundly increased in Stat1DM/PMN mice upon infection, whereas
it remained largely unchanged in Stat1fl/fl mice (Figure 2C). Flow
cytometric analysis using annexin V and viability dye staining
revealed an increased apoptosis of CD11b/low F4/80+ macro-
phages (mainly redpulpmacrophages), neutrophils, andNKcells
in Stat1DM/PMN compared with Stat1fl/flmice at day 3 p.i. (Figures
2D–2F). Apoptosis of CD11b+ F4/80+ cells containing macro-2396 Cell Reports 26, 2394–2406, February 26, 2019phages and monocytes (also eosinophils
and some DCs), CD11b+ F4/80 mono-
cytes and DCs, and inflammatory mono-
cytes (CD11b+ F4/80 Ly-6C+) did not
significantly differ between genotypes
(Figure S2F). Furthermore, T cell and
B cell apoptosis was unaltered when
comparing MCMV-infected Stat1DM/PMN
and Stat1fl/fl mice (Figure S2E).
Taken together, these data indicate
that STAT1 in myeloid cells has organ-
specific effects during the early immune
response to MCMV: although it does not
contribute to tissue damage in the liver,
it inhibits viral replication and protectsCD11b/low F4/80+ macrophages, neutrophils, and NK cells
from apoptotic death in the spleen.
Impaired Early Control of MCMV Infection in
Stat1DM/PMN Mice Is Partially NK Cell Independent
NK cells are crucial for the early control of MCMV (Babic et al.,
2011). We analyzed the production of IFNg by splenic NK cells
at 36 h p.i., the time point when IFNg production by NK cells rea-
ches peak levels (Loewendorf and Benedict, 2010). As reported
previously, the frequency of NK cells in the spleen decreased
upon MCMV infection (Daniels et al., 2001; Mitrovic et al.,
2012) but did not differ between Stat1DM/PMN and Stat1fl/fl mice
(Figure 3A). IFNg production by NK cells (Figure 3B) and serum
levels of IFNg (Figure 3C) were not affected by the absence of
STAT1 in myeloid cells. Moreover, the frequency of granzyme
B (GZMB)-expressing NK cells was similar in Stat1DM/PMN and
control mice at 36 h, 3 days, and 5 days p.i. (Figures 3D and
S3A). NK cell proliferation was analyzed by measuring cell cycle
distribution using DAPI and Ki67 staining. MCMV infection re-
sulted in a comparable shift of NK cells from G0 toward G1
and S/G2/M in Stat1DM/PMN and control mice, with a peak at
day 3 p.i. (Figure 3E).
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Figure 2. Stat1DM/PMN Mice Have a More
Severe Spleen Pathology and Larger
Numbers of Apoptotic Splenocytes
(A and B) Spleen (A) and (B) liver pathology of
MCMV-infected Stat1fl/fl and Stat1DM/PMN mice
at time points indicated and scored from H&E-
stained sections (PBS: n = 18 or 19, N = 6; MCMV:
n = 8, N = 2).
(C) Spleen sections of MCMV-infectedmice (day 3
p.i.) stained for cleaved caspase-3. Representa-
tive pictures and quantifications (left scale bar,
100 mm; right scale bar, 20 mm; n = 5–8, N = 2).
(D–F) Flow cytometric analysis of apoptotic cells
in spleens from MCMV-infected Stat1fl/fl and
Stat1DM/PMNmice (day 3 p.i.). Percentage of viable,
early apoptotic, and late apoptotic CD11b/low F4/
80+ cells (D), neutrophils (E), and NK cells (F) at day
3 p.i. and representative fluorescence-activated
cell sorting (FACS) plots (n = 7 or 8, N = 2).
Mean percentages ± SEM are given. n, biological
replicates; N, experimental repetitions. *p% 0.05
(statistical significance between the genotypes);
#p% 0.05, ##p% 0.01, ###p% 0.001, and ####p%
0.0001 (statistical significance relative to the PBS
control).
See also Figure S2.In C57BL/6 mice, MCMV-infected cells are predominantly
recognized through interactions of the Ly49H receptor on NK
cells with the m157 protein of MCMV (Arase et al., 2002). To
test whether impaired virus control in Stat1DM/PMN mice still oc-
curs in the absence of Ly49H/m157-dependent NK cell re-
sponses, we made use of a mutant MCMV that lacks m157
(Dm157-MCMV) (Bubic et al., 2004). We found higher Dm157-
MCMV titers in spleens from Stat1DM/PMN mice compared with
Stat1fl/fl mice (Figure 3F). Thus, the suppression of splenic
MCMV replication by myeloid STAT1 is at least in part indepen-Cell Repordent of the NK cell ability to control viral
replication through Ly49H-dependent
recognition. We next depleted NK cells
and analyzed viral load in spleens from
wild-type MCMV-infected mice. As ex-
pected, viral load increased in both geno-
types upon NK cell depletion (Figure 3G).
Stat1DM/PMN mice still exhibited a higher
MCMV load than Stat1fl/fl mice after NK
cell depletion, although the difference
was less pronounced than in PBS con-
trols (Figure 3G). Thus, the suppression
of splenic MCMV replication by myeloid
STAT1 is partly, but not completely, inde-
pendent of NK cells.
STAT1 Signaling in Myeloid Cells
Promotes Extramedullary
Hematopoiesis during MCMV
Infection
The spleen functions as a site for
EMH, particularly under stress conditions(Chiu et al., 2015; Kim, 2010). Splenomegaly and spleen rupture
caused by excessive EMH is a complication of CMV infection in
humans (Alliot et al., 2001; Duarte et al., 2003). In support of
previous studies (Jordan et al., 2013; Loh and Hudson, 1981;
Lucia and Booss, 1981), Stat1fl/fl mice developed profound
splenomegaly during MCMV infection, as indicated by a high
spleen weight and elevated splenocyte numbers (Figures 4A
and 4B). In contrast, spleen weight only modestly increased in
Stat1DM/PMNmice (Figure 4A), and total cellularity did not change
upon infection (Figure 4B). We next histologically analyzed thets 26, 2394–2406, February 26, 2019 2397
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Figure 3. Increased Virus Titers in Stat1DM/PMN Mice Are Partially, but Not Completely, Dependent on NK Cells
(A and B) Percentage of NK cells in controls (PBS) and MCMV-infected Stat1fl/fl and Stat1DM/PMN mice (A) and (B) percentage of IFNg-producing NK cells and
representative FACS plots (n = 3–6, N = 2).
(C) Plasma levels of IFNg determined by ELISA (n = 9, N = 2).
(D) The percentage of GZMB-positive NK cells with representative FACS plots (n = 7–12, N = 2).
(E) NK cell proliferation of MCMV-infected and control (PBS) mice was evaluated at the times indicated by flow cytometry using DAPI/Ki67 double staining (n = 8,
N = 2).
(F) Viral load in spleens from Stat1fl/fl and Stat1DM/PMN mice infected i.p. with 5 3 105 PFU of Dm157- MCMV (n = 4 or 5, N = 1).
(G) Viral load in spleens of MCMV-infected mice after NK cell depletion (aNK1.1) or control (PBS) treatment (n = 10, N = 2).
Horizontal lines and error bars indicate mean ± SEM. **p% 0.01, ***p% 0.001, and ****p% 0.0001 (statistical significance between the genotypes); ###p% 0.001
and ####p% 0.0001 (statistical significance relative to the PBS control). n, biological replicates; N, experimental repetitions.
See also Figure S3.abundance of megakaryocytes, which is frequently used
as an indicator of EMH (Lai et al., 1996; Villeval et al., 1997).
Megakaryocyte numbers increased upon infection in Stat1fl/fl
mice, while they remained unchanged in Stat1DM/PMN mice (Fig-
ure 4C), indicating that Stat1DM/PMNmice fail to induce infection-
triggered EMH. Stat1DM/PMN and Stat1fl/fl mice showed compa-
rable reductions of bone marrow cells and erythroblasts (total
numbers and frequencies) upon MCMV infection (Figure S4A),
thus excluding the possibility that the bone marrow is not sup-
pressed in the absence of myeloid STAT1.
EMH upon MCMV infection results in increases of monocytes,
macrophages, neutrophils, and erythroid cells, with a predomi-
nance of the erythroid lineage (Jordan et al., 2013). We found
smaller numbers of erythroblasts, macrophages, and mono-
cytes (CD11b/low F4/80+, CD11b+ F4/80+, and CD11b+
F4/80 monocytes and/or DCs), NK cells, and B cells in infected
Stat1DM/PMNmice than in littermate controls, whereas neutrophil2398 Cell Reports 26, 2394–2406, February 26, 2019(PMN) and T cell numbers did not differ between genotypes (Fig-
ures 4D and S4B).
Erythrocyte precursors (stages I, II, III, and IV) follow a 1:2:4:8
ratio, with stage I referring to proerythroblasts, stage II to baso-
philic erythroblasts, stage III to polychromatic erythroblasts, and
stage IV to orthochromatic erythroblasts (Liu et al., 2013). MCMV
infection did not grossly alter the relative abundance of erythroid
precursors in Stat1fl/fl mice, whereas Stat1DM/PMN mice had a
lower frequency of stage III precursors than Stat1fl/fl mice upon
MCMV infection (Figure 4E). Thus, the absence of STAT1 in
myeloid cells not only results in reduced numbers of erythro-
blasts but also alters the erythroid precursor cell composition
during MCMV infection.
To functionally confirm the defect in EMH in Stat1DM/PMN
mice, we analyzed the numbers of splenic hematopoietic pro-
genitor cells using colony formation assays. Consistent with
previous studies (Jordan et al., 2013), MCMV infection induced
0
50
100
150
200
250
Sp
le
en
w
ei
gh
t[
μg
]
PBS
****
5 days p.i.
0
2
4
6
8
C
el
ls
x
10
7 /
sp
le
en **
PBS 5 days p.i.
0
5
10
15
BF
U
-E
/2
x1
05
ce
lls
PBS 5 days p.i.
***
BFU-E
0
10
30
60
90
120
150
C
FU
-G
/2
x1
05
ce
lls
PBS 5 days p.i.
*
CFU-G
0
5
10
15
20
C
FU
-M
/2
x1
05
ce
lls
PBS 5 days p.i.
CFU-M
A B C D
0
2
4
6
8
M
KC
/1
0H
PF
**
PBS 3 days p.i.
E
F
0
20
40
60
80
100
Ly
m
ph
oc
yt
es
[%
]
days p.i.
PBS 3 5 9
****
Lymphocytes
G
0
10
20
30
40
50
G
ra
nu
lo
cy
te
s
[%
]
days p.i.
PBS 3 5 9
****
Granulocytes
0
2
4
6
8
M
on
oc
yt
es
[%
]
days p.i.
PBS 3 5 9
p=0.06
MonocytesH
0
2
4
6
8
10
12
R
BC
x
10
6 /
μl
days p.i.
PBS 3 5 9
*
RBC
Stat1ΔM/PMN
Stat1fl/fl
Stat1ΔM/PMN
Stat1fl/fl
Stat1ΔM/PMN
Stat1fl/fl
Stat1ΔM/PMN
Stat1fl/fl
0
10
20
30
40
50
60
70
Te
r1
19
+
er
yt
hr
ob
la
st
s
[%
]
5 days p.i.PBS
p=0.05
I II III IV I II III IV
0
2000
4000
6000
8000
10000
W
BC
/μ
L
days p.i.
PBS 3 5 9
*
WBC
0
5
10
15 p=0.1
days p.i.
PBS 3 5 9
**
Platelets
0
5
10
15
20
C
FU
-G
EM
M
/2
x1
05
ce
lls
PBS 5 days p.i.
CFU-GEMM
PBS 5 days p.i.
0 50K 100K 150K 200K 250K
0
-10
3
103
104
105
0 50K 100K 150K 200K 250K
0
-10
3
103
104
105
Stat1fl/fl
Stat1ΔM/PMN
Stat1fl/fl
Stat1ΔM/PMN
I
II
III
IV
I
II
III
IV
I
II
III
IV
I
II
III
IV
C
D
44
FSC-A
0
5
10
15
PMN NK cells
**
0.0
0.5
1.0
1.5
2.0
C
el
ls
x
10
5 /
sp
le
en
C
el
ls
x
10
5 /
sp
le
en
*
*
CD11b-/lowF4/80+
0
1
2
3
C
el
ls
x
10
7 /
sp
le
en
***
Erythroblasts
0
2
4
6
8
10
C
el
ls
x
10
5 /
sp
le
en
CD11b+ F4/80+
*
Pl
at
el
et
s
x
10
5 /μ
l
# # # #
# # # #
# # # #
# # # #
# # # #
# # # ## # # #
# # # #
# # #
# #
# #
#
# # #
# #
# #
# #
# #
# # # #
# # # # # # # #
# # # #
# # # #
# # # # # # # #
# # # # # # # #
# # # #
# # # #
# # # #
# # # #
#
Figure 4. Stat1DM/PMN Mice Have Impaired Extramedullary Hematopoiesis during MCMV Infection
(A and B) Spleen weight (A) and (B) cellularity in MCMV-infected Stat1fl/fl and Stat1DM/PMN mice.
(C) Number of megakaryocytes (MKC) per field counted on H&E-stained spleen sections.
(D) Total numbers of cell types indicated analyzed by flow cytometry.
(E) Erythrocyte precursor composition among erythroblasts in spleens according to size and CD44 expression.
(F) Number of hematopoietic progenitors determined by colony forming assays from spleen homogenates (day 5 p.i.).
(legend continued on next page)
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increases in BFU-E, CFU-M, CFU-G, and CFU-GEMM in
Stat1fl/fl mice (Figure 4F). The number of BFU-E did not in-
crease in Stat1DM/PMN mice, supporting a crucial role of
myeloid STAT1 in MCMV-induced splenic erythropoiesis (Fig-
ure 4F). CFU-M and CFU-GEMM were unaltered, whereas the
number of CFU-G was higher in Stat1DM/PMN than in Stat1fl/fl
mice (Figure 4F).
To investigate whether differences in EMH correlate with dif-
ferences in blood cell composition, we performed differential
blood cell analysis on days 3, 5, and 9 p.i. (Figures 4G and 4H).
MCMV infection caused severe cytopenia, as indicated by
strong decreases in platelet and white blood cell (WBC) counts
at day 3 p.i. (Figure 4G). Red blood cells (RBCs) modestly
decreased upon MCMV infection at day 5 p.i. (Figure 4G). The
decrease in RBC counts upon MCMV infection is comparable
with those reported using other infection and inflammation
models (Johns et al., 2009; Noyes et al., 2009; Schubert et al.,
2008) and satisfies the definition of anemia (i.e., RBC counts
lower than 2 SDs below the average of a population; Raabe
et al., 2011). Stat1DM/PMN mice showed reduced platelet and
RBC numbers compared with Stat1fl/fl mice at days 5 and 9,
respectively (Figure 4G), indicating that blood cell recovery is de-
layed in the absence of myeloid STAT1. Moreover, lymphocyte
abundance was lower and granulocyte abundance higher in
Stat1DM/PMN than in Stat1fl/fl mice on day 5 p.i. (Figure 4H).
Taken together, these results suggest that myeloid STAT1
promotes extramedullary erythropoiesis and megakaryopoiesis
and directly or indirectly restricts granulopoiesis during MCMV
infection.
MCMV Infection Promotes EMH in the Absence of
IFNAR1 or IFNGR2 in Myeloid Cells or the Complete
Absence of IL-27Ra
Among cytokines that activate STAT1, type I and type II IFNs
regulate stress-induced hematopoiesis in the bone marrow by
multiple mechanisms, including direct effects on hematopoietic
stem cells (HSCs) and various hematopoietic progenitors (Bal-
dridge et al., 2010; de Bruin et al., 2014; Ehninger et al., 2014;
Essers et al., 2009; Haas et al., 2015; Hirche et al., 2017; Sato
et al., 2009). More recently, IL-27 has been shown to promote
the expansion of HSCs and myeloid progenitors in the bone
marrow (Furusawa et al., 2016). To test potential upstream
signals, we made use of Ifnar1DM/PMN, Ifngr2DM/PMN, and IL-
27Ra-deficient mice (Il27ra//Wsx1/). As EMH correlates
with splenomegaly and the abundance of erythroblasts (Jordan
et al., 2013; Figure 4), we determined the extent of EMH on the
basis of these parameters. Surprisingly, neither conditional
loss of type I or type II IFN responsiveness in myeloid cells nor
complete loss of IL-27 responsiveness was each individually suf-
ficient to decrease splenomegaly and splenic erythropoiesis
(Figures 5A–5C, 5F–5H, and 5K–5M). Ifnar1DM/PMN had an even(G and H) Blood cell composition determined with a Vet ABC analyzer. Total
monocytes, and granulocytes (H).
In (A), (B), (D), and (E), n = 9–12, N = 3; in (C) and (F), n = 6–8, N = 2; and in (G) and
***p % 0.001, and ****p % 0.0001 (statistical significance between the genotype
nificance relative to the PBS control). n, biological replicates; N, experimental re
See also Figure S4.
2400 Cell Reports 26, 2394–2406, February 26, 2019modestly increased splenomegaly, although this did not trans-
late into an increase in total splenocyte and erythroblast
numbers (Figures 5A–5C). However, IL-27Ra deficiency resulted
in a shift in the erythroblast composition from stage II and III to-
ward stage I erythroblasts (Figure 5N), indicating that IL-27
signaling affects erythroblast differentiation during MCMV infec-
tion. Modest alterations in erythroblast composition were
also observed in Ifngr2DM/PMN mice (Figure 5I). In contrast to
Stat1DM/PMN mice, Ifnar1DM/PMN, Ifngr2DM/PMN, and Il27ra/
mice did not have decreased platelet counts compared with
control mice (Figures 5E, 5J, and 5O).
Taken together these data show that neither type I or type II
IFN signaling in myeloid cells nor IL-27 activity is individually
required for EMH in response to MCMV infection.Inflammation-Associated EMHCrucially Depends on the
Presence of STAT1 in Myeloid Cells
Having established that STAT1 drives splenic EMH during
MCMV infection, we next asked the question whether this ex-
tends to inflammation-associated EMH. Hence, we induced
sterile systemic inflammation by challenging mice with synthetic
CpG-motif containing oligodeoxynucleotides (CpG-ODN), which
induce; EMH with massive erythropoiesis at day 6 post-injection
(Sparwasser et al., 1999). Stat1DM/PMNmice reacted with a com-
parable phenotype upon CpG-ODN challenge as during MCMV
infection: spleen weight and cellularity remained almost un-
changed in Stat1DM/PMN mice, whereas they strongly increased
in Stat1fl/flmice (Figures 6A and 6B). In addition, splenic erythro-
blast numbers were lower in Stat1DM/PMN than in Stat1fl/fl mice
(Figure 6C), suggesting that CpG-ODN-induced EMH is impaired
in these mice. Moreover, CpG-ODN-challenged Stat1DM/PMN
mice had fewer monocytes and/or macrophages, B cells, and
NK cells than control mice (Figures 6D and S5A), although the
differences were less pronounced than during MCMV infection.
Splenic erythroid precursor composition differed between
Stat1DM/PMN and Stat1fl/fl mice upon CpG-ODN challenge (Fig-
ure 6E), although the stages affected were different compared
with MCMV infection. As reduced EMH correlated with
enhanced splenic cell death after MCMV infection, we per-
formed immunohistochemical staining for cleaved Casp3.
CpG-ODN treatment induced considerable splenocyte
apoptosis in both Stat1fl/fl and Stat1DM/PMN mice. In contrast to
MCMV infection, we did not detect differences between geno-
types (Figures 6F and 6G), indicating that STAT1 promotes
EMH independent of its anti-apoptotic activity.DISCUSSION
In this study we identified a crucial contribution of myeloid cells
to the early antiviral defense against MCMV and discovered anumbers of platelets, RBC, and WBC (G) and percentage of lymphocytes,
(H), n = 10–14, N = 2 or 3. Mean values ± SEM are given. *p% 0.05, **p% 0.01,
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Figure 5. MCMV Infection Promotes EMH in the Absence of IFNAR1 or IFNGR2 in Myeloid Cells and in the Complete Absence of IL-27Ra
(A–C, F–H, and K–M) Spleen weight (A, F, and K), (B, G, and L) cellularity, and (C, H, andM) total number of erythroblasts per spleen of Ifngr2DM/PMN, Ifnra1DM/PMN,
and Il27ra/ mice 5 days after MCMV infection.
(D, I, and N) Erythrocyte precursor composition among erythroblasts in spleens according to size and CD44 expression (day 5 p.i.).
(E, J, and O) Blood platelet counts determined with a Vet ABC analyzer (day 5 p.i.).
In (A)–(E) and (K)–(O), n = 8–14, N = 2; and in (F)–(J), n = 17–19, N = 3.Mean values ±SEMare given. *p% 0.05, **p% 0.01, and ***p% 0.001 (statistical significance
between the genotypes); #p% 0.05, ##p% 0.01, ###p% 0.001, and ####p% 0.0001 (statistical significance relative to the PBS control). n, biological replicates;
N, experimental repetitions.novel function of STAT1 in stress-induced hematopoiesis in the
spleen.
The role of monocytes and macrophages in the context of
CMV infection is poorly understood. Conditional ablation of
Stat1 allowed us to study the importance of STAT1 in myeloid
cells in the immune response to MCMV. Monocytes and
macrophages are target cells for MCMV in vivo and believed to
promote dissemination of MCMV to distal organs (Daley-Bauer
et al., 2014; Hanson et al., 1999; Henry et al., 2000; Hsu et al.,
2009; Stoddart et al., 1994). We show that myeloid cells require
STAT1 to restrict early MCMV infection and to prevent infection-
associated tissue damage in the spleen. STAT1 may inhibit viral
replication through its cell-intrinsic antiviral activity and by
facilitating NK cell survival. Although it must be taken intoconsideration that LysM-Cre is expressed not only in monocytes
andmacrophages but also in neutrophils (Clausen et al., 1999), a
recent study excluded a contribution of neutrophils to the de-
fense against MCMV in the spleen (Stacey et al., 2014). It also
seems unlikely that neutrophils disseminate MCMV to the sali-
vary glands, as they are relatively short-lived cells and are not
productively infected by MCMV (Stacey et al., 2014). In support
of studies with clodronate-mediated depletion of macrophages
(Hanson et al., 1999), we observed little impact of STAT1 defi-
ciency in myeloid cells on MCMV infection in the liver. Organ
specificity may reflect MCMV tropism, as macrophages are the
major target cell in the spleen (Hanson et al., 1999), whereas
the contribution of monocytes and macrophages to MCMV
control in the liver may be masked by the high susceptibility ofCell Reports 26, 2394–2406, February 26, 2019 2401
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Figure 6. Stat1DM/PMN Mice Have Impaired Extramedullary Hematopoiesis during Sterile Inflammation
(A and B) Spleen weights (A) and (B) cellularity in Stat1fl/fl and Stat1DM/PMN mice 6 days after injection of 10 nM CpG-ODN.
(C and D) Total numbers of erythroblasts (C) and (D) cell types indicated were analyzed using flow cytometry.
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###p% 0.001, and ####p% 0.0001 (statistical significance relative to the PBS control). n, biological replicates; N, experimental repetitions.hepatocytes to MCMV infection (Sacher et al., 2012). Alterna-
tively, functional heterogeneity of tissue resident macrophages
(Gordon et al., 2014) may account for organ specificity. Our
finding that in contrast to type I IFNs (Crane et al., 2009; Hoke-
ness et al., 2005), STAT1 in myeloid cells is not involved
in the induction of Ccl2 and the recruitment of NK cells
supports previous studies indicating that Ccl2 is induced by
type I IFN in a STAT1-independent manner (Zimmerer et al.,
2007) and underscores the importance of STAT1-independent
responses to IFNs to the immune response against MCMV (Gil
et al., 2001).2402 Cell Reports 26, 2394–2406, February 26, 2019In addition to the role of STAT1 in the antiviral defense, our
study uncovered an unexpected function in the induction of
splenic EMH, as evidenced by decreased splenomegaly,
decreased megakaryocyte and erythroblast numbers, and a
marked decrease in BFU-E in MCMV-infected Stat1DM/PMN
mice compared with littermate controls. This correlated with a
delayed recovery of Stat1DM/PMN mice from MCMV-induced
peripheral blood thrombocytopenia and anemia and a more
persistent MCMV-induced shift of WBCs from lymphocytes to
granulocytes. As bone marrow failure frequently occurs during
CMV infection after transplantation and is associated with
pancytopenia and a poor prognosis, our findings are of clear clin-
ical significance (Almeida-Porada and Ascensao, 1996; Lin et al.,
2011; Mutter et al., 1988; Sato et al., 2011; Sing and Ruscetti,
1995). EMH is a compensatory response to hematopoietic stress
in humans andmice and is frequently induced bymicrobial infec-
tions (Chiu et al., 2015). During CMV infection, EMH causes
splenomegaly, with splenic rupture being a rare but fatal compli-
cation (Alliot et al., 2001; Duarte et al., 2003). The crucial role of
macrophages in homeostatic and stress-induced hematopoiesis
in the bone marrow and in stress-induced EMH is just beginning
to emerge (Chow et al., 2013; McCabe and MacNamara, 2016).
We show that myeloid cells promote EMH through a process
that requires STAT1. Importantly, STAT1 not only facilitates
EMHduringMCMV infection but also during sterile inflammation.
This indicates that the EMH-promoting function of STAT1 may
be separated from its antiviral activity and contributes to
compensatory hematopoiesis under diverse inflammatory con-
ditions. Further investigations will be required to delineate the
exact mechanism for how myeloid STAT1 induces EMH. It is
attractive to speculate that during MCMV infection, the main
EMH-promoting function of STAT1 is to directly or indirectly pro-
tect macrophages from cell death. Our data indicate that the
cell-protective activity of STAT1 is not the sole mechanism for
how STAT1 drives EMH, as we did not observe differences
in splenocyte apoptosis between Stat1DM/PMN and Stat1fl/fl
mice upon CpG-ODN treatment. Interestingly, our data suggest
that during MCMV infection, myeloid STAT1 drives extramedul-
lary erythropoiesis and megakaryopoiesis. Replenishment of
blood platelets during systemic inflammation depends on the
activation of a stem cell-like megakaryocyte progenitor in the
bonemarrow (Haas et al., 2015). Splenic macrophagesmay acti-
vate these specialized progenitors or facilitate their proliferation
and differentiation by shaping the local cytokine milieu (M€uller-
Newen et al., 2017). Macrophages are important constituents
of the erythropoietic niche, termed erythroblastic islands (EIs),
in bone marrow and spleen. Within EIs, macrophages regulate
erythropoiesis by various adhesive signals and soluble factors
(Chasis and Mohandas, 2008; Johns and Christopher, 2012),
suggesting that STAT1 might promote extramedullary erythro-
poiesis through upregulating some of these factors and signals,
although this clearly requires further investigation.
It has remained elusive whether STAT1 in myeloid cells re-
quires cytokine-induced activation to promote EMH. We show
that IFNg signaling in myeloid cells is not required for MCMV-
induced EMH, which is in line with the unimpaired splenomegaly
and expansion of Ter119+ erythroid cells uponMCMV infection in
spleens of mice with complete IFNGR1 deficiency (Jordan et al.,
2013). Furthermore, we did not find evidence for involvement of
type I IFNs and IL-27. Future studieswill be required to determine
whether this is due to redundancies in cytokine-induced re-
sponses, involvement of other STAT1-activating cytokines, or
STAT1 functions that do not rely on cytokine-induced activation.
IFNg is associated with the loss of bone marrow HSCs during
severe anemia (de Bruin et al., 2014), which was recently attrib-
uted to IFNg signaling in macrophages during aplastic anemia
induced by sublethal irradiation and bulk splenocyte transfer
(McCabe et al., 2018). We show that MCMV infection results in
reduced bone marrow cellularity and erythroblast abundancein the absence of myeloid STAT1. This finding argues against
a requirement for IFNg signaling in macrophages for MCMV-
induced bone marrow suppression and is consistent with
earlier studies indicating that short-term exposure to IFNg during
microbial infection is not detrimental to the host (de Bruin et al.,
2014).
Collectively, our study reveals STAT1-dependent activities of
myeloid cells as essential components of the immune defense
against MCMV. Moreover, we show that STAT1 in myeloid cells
is an essential driver of EMH under stress conditions, in partic-
ular of the erythroid and megakaryocytic lineage, marking it as
potential therapeutic target to treat bone marrow failure caused
by CMV infection and possibly other diseases that involve EMH.
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EXPERIMENTAL MODELS AND SUBJECT DETAILS
Mice
Stat1DM/PMN (Stat1flox/flox/LysMCre) were described previously (Wallner et al., 2012). Ifnar1DM/PMN and Ifngr2DM/PMNmicewere gener-
ated by crossing Ifnar1fl/fl (Kamphuis et al., 2006) or Ifngr2fl/flmice (Lee et al., 2015) with LysMCre-mice (Clausen et al., 1999). Ifngr2fl/fl
mice were kindly provided by Werner M€uller (Technical University Braunschweig, Germany). IL-27Ra-deficient mice (Il27ra//
Wsx1/, B6N.129P2-Il27ratm1Mak/J) were from The Jackson laboratory. Littermate controls, wild-type mice and mice heterozygous
for the Cre recombinase were used as controls for the experiments. Experiments were performed with age- and sex-matched
(8 - 12 weeks old) mice. All mice were on C57BL/6 background and bred at the University of Veterinary Medicine Vienna under
specific pathogen-free conditions according to Federation of European Laboratory Animal Science Associations (FELASA) guide-
lines. All animal experiments were approved by the institutional ethics and animal welfare committee and the national authority ac-
cording to xx 26ff. of Animal Experiments Act, Tierversuchsgesetz 2012 - TVG 2012 (BMWF 68.205/0243-II/3b/2011, BMWFW
68.205/0032-WF/II/3b/2014, BMWFW 68.205/0212-WF/V/3b/2016 and BMBWF-68.205/0134-V/3b/2018).
Cells
Mouse embryonic fibroblasts (MEFs) were isolated from C57BL/6N mice. Briefly, 13-14 days old embryos were dissected and, after
removing heads and livers, minced with scissors and resuspend in PBS supplemented with penicillin (50 mg/ml) and streptomycin
(50 U/ml). The suspension was passed through a 100 mm nylon cell strainer and centrifugated at 200 3 g for 5 min. The pellet
was washed with PBS two times and 53 106 cells were plated per 10 cm dish in DMEM (high glucose), 10% FCS (heat-inactivated),
Pen/Strep (100 mg/ml and 100 U/ml), 2mM L-glutamine and 50mM b-mercaptoethanol. Cells were split when confluent or stored in
liquid nitrogen in 10% DMSO in FCS.
Viruses
The murine cytomegalovirus (MCMV) used in this study was a salivary gland-derived (SG) Smith strain (American Type Culture
Collection, ATCC VR194). The Dm157-MCMV strain (Bubic et al., 2004) was tissue culture-derived (TC).
METHOD DETAILS
In vivo infection/CpG-ODN injection
Mice were infected intraperitoneally (i.p.) with SG-MCMV or Dm157-MCMV at the dose indicated. CpG-ODN was injected i.p. at a
dose of 10 nmol. PBS was used as a control. In all cases the injected volume was 200 ml.e2 Cell Reports 26, 2394–2406.e1–e5, February 26, 2019
Plaque assay
Organs were mashed through a 100 mm nylon cell strainer followed by homogenization with a Wheaton tight-fitting pestle (Figure 1,
Figure 3F) or organs were homogenized in PBS with an automated tissue homogenizer (1500 rpm, 90 s, MiniG, SPEX) (Figure 3G).
Plaque assays were performed using primary MEFs (at passage numbers below 5 and grown to sub-confluence) using centrifugation
enhancement (room temperature, 30min, 1103 g) followed by 90min incubation at 37C, 5%CO2. Virus inoculumwas removed and
cells were overlaid with 1% of low-melting agarose in growth medium. MCMV plaques were counted under microscope 3 to 4 days
later.
RT-qPCR for MCMV genome copies
Genomic DNA was isolated from homogenized tissues after proteinase K digestion using phenol/chloroform/isoamyl alcohol purifi-
cation, followed by precipitation with isopropanol andwashing with ethanol (70%). The DNA pellet was dissolved in TE-buffer and the
DNA concentration was determined using Nano Drop. RT-qPCR was performed with primers for MCMV m54 (300 nM):
m54-fwd 50-CATCCGTTGCATCTCGTTG-30,
m54-rev 50-ACGTACATCGCTCTCTGCTG-30.
The RT-qPCR mixture was composed of 4mM MgCl2, 100 nM Evagreen
 (Biotium), 1 U/rxn Hotfire Polymerase (Solis BioDyne),
200 mM dNTP mix and 1x Hotfire B buffer. PCR conditions were: 15 min at 95C and 40 cycles 95C for 20 s and 60C for 1 min. For
absolute quantification of the genome copies, a standard curve was obtained using serial dilutions of DNA from purified TC-MCMV.
Blood analysis and transaminase measurements
Differential blood analysis was performed with Scil Vet abc hematology analyzer. Blood was centrifugated at 30003 g for 10min and
transaminases were measured in plasma using VetTest 8008.
Histology and immunohistochemistry
Organs were fixed in 10% formalin for 24 h and embedded in paraffin, cut into 4 mm sections, stained with hematoxylin and eosin
(H&E) and scored by a trained pathologist, who was blinded for the groups. Scoring of liver pathology was performed as described
(Tang-Feldman et al., 2011) and included interface activity, intralobular inflammation and necrosis, portal inflammation (0 = absent,
1 = mild, 2 = moderate, 3 = moderately severe, 4 = severe) and steatosis (0 = absent, 1 = present). The scoring of spleen pathology
mainly focused on parameters of cell death, such as apoptosis, necrosis and cell proliferation in the marginal zone (0 = absent,
1 = mild, 2 = moderate, 3 = severe) as well as siderosis (0 = absent, 1 = mild/moderate, 2 = severe). For immunohistochemistry,
in brief, de-paraffinized samples were rehydrated, endogenous peroxidase activity was blocked using 3% H2O2 and samples
were subjected to antigen retrieval using 10 mM citrate buffer (pH 6, Vector labs). After several blocking steps, sections were incu-
bated at 4C overnight with either anti-mouse cleaved caspase 3 antibody (clone 5A1E, Cell Signaling Technologies) or anti-m123
antibody (Croma 101). After washing steps and incubation with a corresponding secondary antibody, visualization was achieved
using the Vectastain ABC kit (Vector Labs), the slides were counterstained with hematoxylin and images were acquired using a Zeiss
Axio imager microscope. Quantification of positive cells was performed by counting cells/field in 5 pictures per mouse (20-fold or
10-fold magnification), blinded for the groups.
RNA isolation and real-time qPCR
RNA was isolated using TRIzol reagent (Invitrogen) and reverse transcription was performed using iScript First Strand cDNA Synthe-
sis Kit (Bio-Rad). Quantitative PCR for Ccl2 and Ccl5 was done with QIAGEN assays and the Evagreen detection system. Ube2d2
was used as housekeeping gene with the following primers and FAM-labeled probe:
Ube2d2-fwd 50-AGG TCC TGT TGG AGA TGA TAT GTT-30,
Ube2d2-rev 50-TTGGGAAATGAATTG TCA AGA AA-30,
Ube2d2-probe 50-FAM-CCA AAT GAC AGC CCC TAT CAG GGT GG-BHQ-30.
The RT-qPCR mixture was composed of 4mMMgCl2, 100 nM Evagreen
 or FAM probe (for Ube2d2), 1 U/rxn Hotfire Polymerase
(Solis BioDyne), 200 mMdNTPmix and 1x Hotfire B buffer. PCR conditions were: 15min at 95C and 40 cycles 95C for 20 s and 60C
for 1 min.
In vivo NK cell depletion assay
NK cells were depleted using anti-NK1.1 antibody (clone PK136, InVivoMab). 300 mg of the antibody was injected i.p. 24 h before and
36 h after MCMV infection. Control groups were injected with 200 mL PBS. Spleens were collected 3 days after infection. Depletion
efficiency was determined by FACS analysis of splenic NK cells (Figure S3B).Cell Reports 26, 2394–2406.e1–e5, February 26, 2019 e3
Colony forming unit assay
Five days after MCMV infection, splenocytes were isolated by mashing the spleens through a 100 mm cell strainer. Samples
were centrifugated and erythrocyte lysis was performed. Cells were counted with T€urk solution and 2 3 105 cells were plated
in methylcellulose-based medium that included IMDM, 10% FCS (heat-inactivated), Pen/Strep (100 mg/ml and 100 U/ml), 2 mM
L-glutamine and 50 mM b-mercaptoethanol with recombinant cytokines for mouse (Stem Cell Technology). Colonies were counted
under microscope after 7 days incubation at 37C, 5% CO2. BFU-E, blast-forming unit erythroid; CFU-G, colony-forming unit
granulocyte; CFU-M, colony-forming unit macrophages; CFU-GEMM, colony-forming unit granulocyte, erythrocyte, monocyte,
megakaryocyte.
Flow cytometry
Isolation of cells from spleen, bone marrow and liver
Splenocytes were isolated by mashing the spleens through a 100 mm cell strainer. Femurs were isolated from mice at the indicated
time point, cleaned bones were crushed with mortar and pestle in PBS and mashed through a 100 mm cell strainer. Samples were
centrifuged and erythrocyte lysis was performed in all staining panels, except for the erythroid compartment. Cells were counted
(CASY cell counter, OMNI Life Science). Liver lymphocytes were isolated from euthanized mice after liver perfusion with 10 mL of
PBS, livers were mashed through a 100 mm cell strainer and washed twice with PBS. Enrichment of lymphocytes was done with
37.5% Percoll solution and 2.5 3 106 cells (for extracellular staining) or 5 3 106 cells (for intracellular staining) per sample were
used. Single stains were used to set up the compensation of fluorophores in FACS CantoTM, FACS DivaTM (BD Bioscience) and
FlowJo software (FLOWJO, LLC).
Staining of specific cell types
Cells were first stainedwith Fixable Viability Dye (APCCy7, working solution 1:1000 in PBS) for 5min at room temperature. Cells were
washed with PBS and incubated with antibodies against surface markers at a dilution of 1:200 (except for CD11b, which was used at
1:400) for 20 min at 4C in the dark. Staining panel 1 (Figure 4, Figure 5, Figure 6, Figure S4 and Figure S5): CD16/CD32 Fc block
(unconjugated), CD3ε (eF450), CD19 (APC), CD11b (PerCPCy5.5), Ly-6G (PE), NK1.1 (PeCy7) and F4/80 (FITC). Staining panel 2 (Fig-
ure 4, Figure 5 and Figure 6): CD16/CD32 Fc block (unconjugated), Ter119 (eF450) and CD44 (PE). Cells were washed with PBS and
fixed with 2% PFA for 30 min at room temperature in the dark. Gating strategies are shown in Figures S2G, S4C and S4D.
Apoptosis (Annexin V/LD) staining
Staining was performed using Annexin staining kit according manufacturer’s instructions. Briefly, cells were stained with Fixable
Viability Dye for 5 min at room temperature, washed with PBS and incubated with antibodies against surface markers 20 min at
4C in the dark. Staining panel 1 (Figure 2 and Figure S2): CD16/CD32 Fc block (unconjugated), CD3 (eF450), CD19 (APC),
CD11b (PerCP Cy5.5), NK1.1 (FITC) and Ly-6G (PE). Staining panel 2 (Figure 2 and Figure S2): CD16/CD32 Fc block (unconjugated),
Ly-6C (eF450), CD3/CD19/NK1.1 (APC), CD11b (PerCP Cy5.5), Ly-6G (PE) and F4/80 (FITC). After staining, samples were washed
with PBS, then with binding buffer and stained with Annexin V (PE Cy7) 15 min at room temperature, in dark. Samples were washed
with binding buffer and fixed with intracellular fixation buffer (Intracellular Fixation & Permeabilization Buffer Set).
Intracellular staining for IFNg
Cells were incubated for 20 min at 4C in dark with following antibodies (Figure 3 and Figure S3): CD16/CD32 Fc block (unconju-
gated), CD3 (eF450), NK1.1 (FITC) and NKp46 (PE). Cells were washed with PBS and permeabilized with perm/wash buffer
(Fixation/Permeabilization Solution Kit), according to the manufacturer’s instructions. Intracellular staining was done in perm/
wash buffer with anti-IFNg (APC) antibody for 30 min at 4C in the dark. Cells were washed and fixed with fixation solution.
Intracellular staining for Granzyme B
Splenocytes were incubated for 4 h in 1 mL of Brefeldin A/RPMI (1:1000 dilution) at 37C, 5%CO2, stained with Fixable Viability Dye,
washed with PBS and incubated 20 min at 4C in the dark with following antibodies (Figure 3 and Figure S3): CD16/CD32 Fc block
(unconjugated), CD3ε (eF450), NKp46 (PE) and NK1.1 (PeCy7). Cells were washed with PBS, fixed and permeabilized using Foxp3
Staining Kit according to the manufacturer’s instructions. Intracellular staining was performed in permeabilization buffer with anti-
Granzyme B (APC) antibody for 30 min at 4C in dark. Cells were washed with permeabilization buffer and then with PBS.
Intracellular staining for Ki67/DAPI
Cells were incubated for 20min at 4C in dark with following antibodies (Figure 3): CD16/CD32 Fc block (unconjugated), CD3e (APC),
NKp46 (PE) and NK1.1 (PeCy7). Cells were washed with PBS, fixed for 20 min at room temperature using 200 ml Cytofix (BD, Fix and
Perm). Fixed cells were permeabilized using BD perm washing buffer (1:10 diluted in MilliQ water) and subsequently incubated for
30 min at room temperature with 200 ml staining solution (1g/ml DAPI, 20 ml FITC conjugated anti-Ki67 antibody in PBS containing
0,1% Triton-X). Cells were washed with perm buffer and PBS. The gating strategy is shown in Figure S3C.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical parameters including the exact value of n (number of mice), N (number of experiments), the definition of central value and
spread (mean ± SEM), and statistical significance are reported in the Figure Legends. Statistical analysis for PFU and genome copiese4 Cell Reports 26, 2394–2406.e1–e5, February 26, 2019
of MCMV was done on log-transformed data. None of the data were removed from our statistical analysis as outliers. Data were
considered to be statistically significant when p % 0.05. In figures, asterisks represent statistical significances for comparisons
between genotypes (*p% 0.05, **p% 0.01, ***p% 0.001, ****p% 0.0001) and hashtags represent statistical significances between
MCMV-infected/CpG-ODN-treated mice and respective PBS controls (#p % 0.05, ##p % 0.01, ###p % 0.001, ####p % 0.0001).
P values between 0.05 and 0.1 are indicated for the genotype comparisons. Statistical analysis was performed in GraphPad Prism
7 (Student’s t test and one-way ANOVA with Tukey’s multiple comparison test) or in R-studio IDE (two-way ANOVA, Figure 3G;
https://www.rstudio.com/).Cell Reports 26, 2394–2406.e1–e5, February 26, 2019 e5
